How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?
研究药品共付优惠券对品牌药净价格和销量的因果效应，发现优惠券使商业保险段销量增加23-25%，并使多数多发性硬化症药物净价提高8%。
We estimate the causal effects of drug copayment coupons, which reduce consumer cost-sharing for branded prescription drugs, on net-of-rebate price and quantities sold. Focusing on drugs without generic substitutes, we show that coupon introductions increase quantity sold by 23-25% for the commercial segment relative to Medicare Advantage, where coupons are banned. To quantify the resulting equilibrium price effects, we estimate a discrete choice model of demand for multiple sclerosis drugs and simulate a model of drug price negotiations. We estimate that net-of-rebate prices are 8% higher due to the availability of coupons for most of these drugs.